Alpha Exposure
Contributor since: 2011
Latest Articles
We Believe Janssen Has Separated From Geron. Just Awaiting Divorce Papers
Geron's Negative Imetelstat Data Has Been Misinterpreted By Investors
Imetelstat Might Be Brought Down By Hy's Law
Geron: Imetelstat's History Of Deaths And Safety Issues
Athersys' Zombie-Like MultiStem Won't Survive Much Longer
Newlink And The Curious Case Of The Missing Patients
Eros: Roll The Credits
Achaogen: An Overvalued Antibiotics Company With 85% Downside
Mesoblast: Caught Red-Handed
Mesoblast Is Trying To Fool Investors Again
Oil Doubles, But BPT Should Still Get Cut In Half
Why BPT Should Get Cut In Half Again... And Then Again
Eros: Revising Our TopCo Analysis
Eros: Is The Game Finally Over? We Think So
Eros: Return Of The Short Seller (2015)
Mesoblast, An Aussie Biotech Cooking Up A Turkey For American Investors
Unlike The Name, Investors Should Not Love EROS
Immunomedics - The Trail Of Tears (For Shareholders That Is)
SFX Entertainment: The House Of Cards Is Collapsing
Asterias Biotherapeutics' Stem Cell Program Is Dead On Arrival
Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga
Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia
Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
SFX Entertainment: The Music's About To Stop
SFX Entertainment: Playing House Music In A House Of Cards
VirnetX Obfuscates The Truth: Stock Worth Under $1
VirnetX Patents At High Risk Of Being Invalidated
VirnetX Is Worth Well Under $1 Per Share
ParkerVision: Big Mistake In Suing Samsung
ParkerVision Still Tremendously Overvalued
ParkerVision Bulls Vastly Overstating Pre-Judgment Interest Amount
ParkerVision: Read The Transcript, Short The Stock